ACI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Albertsons (ACI) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The stock has some supportive signs—analyst ratings remain mostly Buy/Outperform, congress members have been net buyers, and valuation sentiment from options is mildly bullish—but the current technical setup is still bearish and the latest quarter shows weaker earnings quality despite solid revenue growth. Since the user is unwilling to wait for a perfect entry, the best direct call is to hold off on a full purchase today and wait for clearer price strength above resistance or a more constructive trend reversal.
Price is 16.15, just above support at 16.005 and below pivot resistance at 16.418. The MACD histogram is negative, RSI_6 at 36.875 is neutral-to-weak, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That means the short- and medium-term trend is still under pressure. Near-term upside exists, but the chart does not yet show a confirmed bullish breakout. The stock trend model suggests mixed behavior: slightly positive next day, negative next week, and stronger performance over the next month.
["Revenue grew 7.73% YoY in the latest quarter (2026/Q4).", "Roth Capital kept a Buy rating and said EBITDA has turned to YoY growth after 12 straight quarters of decline.", "Most major analysts still keep Buy/Outperform-type ratings despite price target cuts.", "Congress trading data shows 3 purchase transactions and 0 sales in the last 90 days, suggesting positive political/influential-fund sentiment.", "Options positioning is call-skewed, implying traders are leaning bullish.", "No negative news headlines in the last week."]
["Latest quarter net income was -$480.8M and EPS was -0.94, both sharply worse YoY.", "Gross margin declined to 27.21%, showing profitability pressure.", "Analysts lowered price targets across the board, including Roth, UBS, RBC, Citi, and JPMorgan.", "JPMorgan noted a lighter-than-expected identical sales outlook and removed ACI from its Analyst Focus List.", "Technical trend is bearish with MACD below zero and moving averages stacked bearishly.", "The stock is trading near support, not in a confirmed uptrend."]
Latest quarter: 2026/Q4. Revenue increased to $20.2522B, up 7.73% YoY, which is a positive top-line trend. But profitability weakened materially: net income fell to -$480.8M, EPS dropped to -0.94, and gross margin slipped to 27.21%. This suggests sales growth is not yet translating into bottom-line strength, even though some analysts believe cost savings and pharmacy mix improvements could help later.
Wall Street remains cautiously constructive. Recent analyst actions were mostly Buy/Outperform maintained, but price targets were lowered: Roth to $23 from $24, UBS to $20 from $23, RBC to $20 from $21, Citi to $22 from $26, and JPMorgan to $22 from $23. The pros view is that Albertsons is making progress on margins, has improving EBITDA trends, and may benefit from efficiency programs. The cons view is muted top-line guidance, pharmacy-related pressure, and weaker identical sales outlook. Overall, analysts are positive on rating but less enthusiastic on valuation targets.
